WO1995023799A1 - Process for the preparation of an indazole-3-carboxamide derivative - Google Patents

Process for the preparation of an indazole-3-carboxamide derivative Download PDF

Info

Publication number
WO1995023799A1
WO1995023799A1 PCT/EP1995/000764 EP9500764W WO9523799A1 WO 1995023799 A1 WO1995023799 A1 WO 1995023799A1 EP 9500764 W EP9500764 W EP 9500764W WO 9523799 A1 WO9523799 A1 WO 9523799A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzyl
methyl
endo
compound
azabicyclo
Prior art date
Application number
PCT/EP1995/000764
Other languages
French (fr)
Inventor
Norman John Lewis
Victor Witold Jacewicz
Neal Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to DE69510186T priority Critical patent/DE69510186D1/en
Priority to EP95912187A priority patent/EP0748321B1/en
Priority to MX9603818A priority patent/MX9603818A/en
Priority to JP52270295A priority patent/JP4034339B2/en
Publication of WO1995023799A1 publication Critical patent/WO1995023799A1/en
Priority to GR990402203T priority patent/GR3031121T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • EP-A-0200444 (Beecham Group pic) describes certain 5-HT (5- hydroxytryptamine) antagonists which are described as possessing a number of therapeutic utilities, inter alia the prevention of vomiting following the administration of cytotoxic agents.
  • the compound described in Example 6 is endo-N-(9-methyl-9- azabicyclo[3.3.1]non-3-yl)-l-methylindazole-3-carboxamide, and this compound has been assigned the INN granisetron.
  • EP-A-0200444 discloses that granisetron can be prepared by reacting l-methylindazole-3-carboxylic acid chloride with endo-3- amino-9-methyl-9-azabicyclo[3.3.1 ]nonane.
  • the present invention provides a process for preparing granisetron (1) or a pharmaceutically acceptable salt thereof:
  • R is a nitrogen-protecting group which does not significantly reduce the nucleophilicity of a secondary amino group, and optionally forming a pharmaceutically acceptable salt.
  • R is benzyl, substituted benzyl, t-butyl, allyl, or a silyl group such as t-butyldimethylsilyl.
  • substituted benzyl include benzyl substituted with one or more chloro, alkyl or alkoxy groups, preferably methyl or methoxy groups.
  • p-Methoxybenzyl and p-chlorobenzyl are two specific examples.
  • the reaction is carried out under conditions appropriate to remove the protecting group.
  • R is benzyl or substituted benzyl the reaction may be carried out by treatment under strongly acidic non-aqueous conditions, e.g. methanesulphonic acid, trifluoroacetic acid, or hydrogen chloride or hydrogen bromide in acetic acid.
  • R is t-butyl the reaction may be carried out under non- aqueous acidic conditions, for example by treatment with trifluoroacetic acid.
  • R is allyl the reaction may be carried using tetrakis(triphenyiphosphine)-palladium(0).
  • Silyl groups such as t-butyldimethylsilyl can generally be removed by treatment under acidic conditions, for example by treatment with hydrogen chloride in ethanol or trifluoroacetic acid, or by treatment with fluoride ion, for example potassium fluoride or tetrabutylammonium fluoride in a lower alkanol such as methanol.
  • fluoride ion for example potassium fluoride or tetrabutylammonium fluoride in a lower alkanol such as methanol.
  • Compounds of Structure (2) can be prepared by reacting an amine of Structure (4), in which R is defined as above, with a compound of Structure (3) in which Q is a leaving group displaceable by a secondary amine.
  • leaving groups displaceable by a secondary amine include halogen, such as chloro and bromo, C ⁇ _6 alkoxy such as methoxy or ethoxy, and N-imidazolyl.
  • the reaction is carried out carried out carried out at ambient or elevated temperature in an organic solvent such as toluene or dichloromethane.
  • This process is advantageous because of its overall selectivity and in particular it does not give rise to bis-acylated products, compared to the process described in EP-A-0200444.
  • the compounds of Structure (4) in which R is benzyl or substituted benzyl can be prepared by reducing an imine of Structure (5) (or a tautomeric enamine thereof); suitably the reduction is carried out using sodium borohydride, sodium cyanoborohydride or lithium aluminium hydride, or by selective catalytic hydrogenation, for example using hydrogen and a palladium catalyst.
  • the imines of Structure (5) can be prepared by condensing a ketone of Structure (6) with benzylamine or a substituted benzylamine, or by reacting the amine of Structure (7) with benzaldehyde or a substituted benzaldehyde.
  • this reaction will be carried out with an acid catalyst under conditions suitable for dehydration e.g. by heating in toluene, or by treatment with titanium tetrachloride or molecular sieve 3A or similar.
  • the compounds of Structure (4) in which R is benzyl, substituted benzyl or allyl can be prepared by reacting the amine of Structure (7) with a benzyl or allyl halide, for example benzyl chloride or allyl bromide.
  • N-Benzyl-N-(endo-9-methyl-9-azabicyclo-[3,3,l]-non-3-yl)-l-methylindazole-3- carboxamide monohydrochloride (1.00 g) and methane sulphonic acid (5.0 ml) were heated at 70°C with stirring for 1.5 hours. TLC showed a strong spot corresponding to granisetron and confirmed that no starting material remained.
  • the solution was cooled to room temperature, poured into ice cold water (200 ml), made alkaline using sodium hydroxide and extracted with dichloromethane (100 ml).
  • the dichloromethane extract was washed twice with water (50 ml), dried over magnesium sulphate and evaporated to a foam. This was treated with toluene (50 ml) and concentrated hydrochloric acid (0.25 g) and again evaporated to dryness.
  • the residue was treated with isopropanol (50 ml) and allowed to crystallise in the cold.
  • the white solid was collected by filtration, washed with a little isopropanol and dried in the oven at 75°C.
  • N-4-Methoxybenzyl-N-(endo-9-methyl-9-azabicyclo-[3,3,l]-non-3-yl)-l- methylindazole-3-carboxamide monohydrochloride (1.00 g) and methane sulphonic acid (5.0 ml) were heated at 70°C with stirring for 20 minutes. TLC showed a strong spot corresponding to granisetron and confirmed that no starting material remained. The cooled mixture was poured into ice cold water, and the product isolated following the method of Example 1(d). Yield 0.57 g (76.6%) IR and NMR spectroscopy confirmed that the product was granisetron.
  • N-4-Methoxybenzyl-N-(endo-9-methyl-9-azabicyclo-[3,3,l]-non-3-yl)-l- methylindazole-3-carboxamide monohydrochloride (1.00 g) was stirred in • trifluoroacetic acid (4.0 ml) at room temperature. After an initial vigorous reaction, the mixture was warmed briefly to 70°C and examined by TLC, which confirmed that the reaction was complete. The mixture was poured into ice cold water (100 ml) and filtered. The filtrate was made alkaline and extracted with dichloromethane (100 ml). The product was isolated from this extract following the method of Example 1(d). Yield 0.41 g (55.0%). IR and NMR spectroscopy confirmed that the product was granisetron.
  • 9-Methyl-9-azabicyclo[3.3.1]nonan-3-one (Ref: Org. Synth Coll Vol. 4. 816) is heated under reflux in toluene with benzylamine with p-toluene sulphonic acid catalysis to give 3-benzimino-9-methyl-9-azabicyclo[3.3.1]nonane. This is reduced with sodium cyanoborohydride in tetrahydrofuran to give 3-benzylamino-9-methyl-9- azabicyclo[3.3.1]nonane.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Catalysts (AREA)
  • Saccharide Compounds (AREA)

Abstract

A process for preparing granisetron (1) or a pharmaceutically acceptable salt thereof, which process comprises deprotecting a compound of Structure (2), wherein R is a nitrogen-protecting group which does not significantly reduce the nucleophilicity of a secondary amino group, and optionally forming a pharmaceutically acceptable salt.

Description

Process for the preparation of an 1 ndazo .e-3-carboxam .de derivative
The present invention relates to a new process for preparing pharmaceutically active compounds and intermediates therefor. EP-A-0200444 (Beecham Group pic) describes certain 5-HT (5- hydroxytryptamine) antagonists which are described as possessing a number of therapeutic utilities, inter alia the prevention of vomiting following the administration of cytotoxic agents. The compound described in Example 6 is endo-N-(9-methyl-9- azabicyclo[3.3.1]non-3-yl)-l-methylindazole-3-carboxamide, and this compound has been assigned the INN granisetron. EP-A-0200444 discloses that granisetron can be prepared by reacting l-methylindazole-3-carboxylic acid chloride with endo-3- amino-9-methyl-9-azabicyclo[3.3.1 ]nonane.
A new process has been devised which is particularly selective and can be used to prepare granisetron in a high state of purity. Accordingly, the present invention provides a process for preparing granisetron (1) or a pharmaceutically acceptable salt thereof:
Figure imgf000003_0001
(1) granisetron
which process comprises deprotecting a compound of Structure (2).
Figure imgf000003_0002
(2) wherein R is a nitrogen-protecting group which does not significantly reduce the nucleophilicity of a secondary amino group, and optionally forming a pharmaceutically acceptable salt.
Preferably R is benzyl, substituted benzyl, t-butyl, allyl, or a silyl group such as t-butyldimethylsilyl. Examples of substituted benzyl include benzyl substituted with one or more chloro, alkyl or alkoxy groups, preferably methyl or methoxy groups. p-Methoxybenzyl and p-chlorobenzyl are two specific examples.
The reaction is carried out under conditions appropriate to remove the protecting group. For example when R is benzyl or substituted benzyl the reaction may be carried out by treatment under strongly acidic non-aqueous conditions, e.g. methanesulphonic acid, trifluoroacetic acid, or hydrogen chloride or hydrogen bromide in acetic acid. When R is t-butyl the reaction may be carried out under non- aqueous acidic conditions, for example by treatment with trifluoroacetic acid. When R is allyl the reaction may be carried using tetrakis(triphenyiphosphine)-palladium(0). Silyl groups such as t-butyldimethylsilyl can generally be removed by treatment under acidic conditions, for example by treatment with hydrogen chloride in ethanol or trifluoroacetic acid, or by treatment with fluoride ion, for example potassium fluoride or tetrabutylammonium fluoride in a lower alkanol such as methanol.
Compounds of Structure (2) can be prepared by reacting an amine of Structure (4), in which R is defined as above, with a compound of Structure (3) in which Q is a leaving group displaceable by a secondary amine. Examples of leaving groups displaceable by a secondary amine include halogen, such as chloro and bromo, Cι_6 alkoxy such as methoxy or ethoxy, and N-imidazolyl. Suitably the reaction is carried out carried out at ambient or elevated temperature in an organic solvent such as toluene or dichloromethane.
Figure imgf000004_0001
(3) (4)
The compounds of Structure (2), and the compounds of Structure (4) in which R is other than benzyl are believed to be novel and form part of this invention.
This process is advantageous because of its overall selectivity and in particular it does not give rise to bis-acylated products, compared to the process described in EP-A-0200444.
The compounds of Structure (4) in which R is benzyl or substituted benzyl can be prepared by reducing an imine of Structure (5) (or a tautomeric enamine thereof); suitably the reduction is carried out using sodium borohydride, sodium cyanoborohydride or lithium aluminium hydride, or by selective catalytic hydrogenation, for example using hydrogen and a palladium catalyst.
Figure imgf000005_0001
(5) The imines of Structure (5) can be prepared by condensing a ketone of Structure (6) with benzylamine or a substituted benzylamine, or by reacting the amine of Structure (7) with benzaldehyde or a substituted benzaldehyde. Suitably this reaction will be carried out with an acid catalyst under conditions suitable for dehydration e.g. by heating in toluene, or by treatment with titanium tetrachloride or molecular sieve 3A or similar.
Figure imgf000005_0002
(6) (7)
Alternatively the compounds of Structure (4) in which R is benzyl, substituted benzyl or allyl can be prepared by reacting the amine of Structure (7) with a benzyl or allyl halide, for example benzyl chloride or allyl bromide.
In this specification compounds are shown in the boat-chair form. It will be recognised that these conformations will be in equilibrium with the corresponding chair-chair forms which are shown in EP-A-0200444.
The following examples illustrate the present invention.
Example 1 a) endo-3-benzylamino-9-methyl-9-azabicyclo-[3,3,l]-nonane [(4), R = benzyl] (i) Preparation of intermediate imine: A mixture of endo-3-amino-9-methyl-9- azabicyclo-[3,3,l]-nonane [15.4 g] and benzaldehyde [10.6 g] in toluene [250 ml] was refluxed in a Dean and Stark apparatus for 45 minutes, when the theoretical amount of water was collected. The solvent was removed on a rotary evaporator to give a colourless oil which crystallised on storage in the refrigerator. MS analysis confirmed the molecular weight of the intermediate imine as 242.
(ii) Reduction to the amine: A solution of the intermediate imine [21.0 g] in ethanol [150 ml] was treated with sodium borohydride [3.8 g] in portions over 5 minutes at room temperature, heated briefly to boiling, then cooled. The solvent was removed on a rotary evaporator, the residue taken up in water [250 ml] and the mixture cautiously acidified with concentrated hydrochloric acid [20 ml]. The acidified solution was washed with dichloromethane [250 ml], then made alkaline with sodium hydroxide and extracted twice with dichloromethane [250 ml]. The combined extracts were washed with water [250 ml], dried with magnesium sulphate and evaporated to give the product as a colourless oil [19.0 g]. MS analysis confirmed the molecular weight of the amine as 244, and the NMR spectrum was consistent with the endo-isomer of the title compound.
b) l-methylindazole-3-carbonyl chloride [(3), Q = chloro]. l-Methylindazole-3-carboxyhc acid [50.0g] and thionyl chloride [200 ml] were refluxed gently for 2 hours, then allowed to cool. The solution was diluted with hexane [800 ml] to give a pale brown crystalline solid. This was collected, washed on the filter with hexane and dried in the oven at 80°C. Yield 39.3 g (71.2%). The IR spectrum (Nujol mull) showed a strong band at 1748 cm~l.
c) N-benzyl-N-(endo-9-methyl-9-a--abicyclo-[3,3,l]-non-3-yl)-l-methylindazole-
3-carboxamide monohydrochloride [(2), R = benzyl]
A solution of endo-3-benzylamino-9-methyl-9-azabicyclo-[3,3,l]-nonane [19.0 g] in toluene [150 ml] was added with stirring to l-methylindazole-3-carbonyl chloride
[15.3 g] in toluene [300 ml] at room temperature over 20 minutes. The resulting suspension was stirred at room temperature for 3 hours, the white solid collected by filtration, washed firstly with toluene, then with hexane, and finally dried in the oven at
100°C. Yield 30.70 g (90%).
MS analysis gave the expected molecular weight (402) for the free base of the title compound. After recrystallisation from isopropanol the product melted at 247 to 248 °C and gave the following elemental analysis:
Found C 68.18, H 7.14, N 12.89;
C25H31N4CIO requires C 68.40, H 7.12, N 12.76%
d) N-(endo-9-methyl-9-azabicyclo-[3 ,l]-non-3-yl)-l-methyIindazole-3- carboxamide monohydrochloride [granisetron (1)].
N-Benzyl-N-(endo-9-methyl-9-azabicyclo-[3,3,l]-non-3-yl)-l-methylindazole-3- carboxamide monohydrochloride (1.00 g) and methane sulphonic acid (5.0 ml) were heated at 70°C with stirring for 1.5 hours. TLC showed a strong spot corresponding to granisetron and confirmed that no starting material remained.
The solution was cooled to room temperature, poured into ice cold water (200 ml), made alkaline using sodium hydroxide and extracted with dichloromethane (100 ml). The dichloromethane extract was washed twice with water (50 ml), dried over magnesium sulphate and evaporated to a foam. This was treated with toluene (50 ml) and concentrated hydrochloric acid (0.25 g) and again evaporated to dryness. The residue was treated with isopropanol (50 ml) and allowed to crystallise in the cold. The white solid was collected by filtration, washed with a little isopropanol and dried in the oven at 75°C. Yield 0.40 g (53.8%) IR and NMR spectroscopy confirmed that the product was granisetron. Example 2 a) endo-3-(4-methoxybenzylamino)-9-methyl-9-azabicyclo-[3,3,l]-nonane [(4), R = 4-methoxybenzyl]
The reaction of endo-3-amino-9-methyl-9-azabicyclo-[3,3,l]-nonane [15.4 g] and 4- methoxybenzaldehyde [13.6 g] using the conditions described in Example l(a)(i) gave the intermediate imine as a crystalline solid. MS analysis confirmed the molecular weight as 272.
Reduction of the intermediate imine [27.0 g] in isopropanol [250 ml] with sodium borohydride [3.9 g] following the method of Example l(a)(ii) gave the title compound as a colourless oil [23.0 g]. MS analysis confirmed the molecular weight of the amine as 274, and the NMR spectrum was consistent with the endo-isomer of the title compound.
b) N-4-methoxybenzyl-N-(endo-9-methyl-9-azabicycIo-[3,3,l]-non-3-yl)-l- methylindazole-3-carboxamide monohydrochloride [(4), R = 4-methoxybenzyl] A solution of endo-3-(4-methoxybenzylamino)-9-methyl-9-azabicyclo-[3,3,l]-nonane [14.0 g] in toluene [75 ml] at room temperature was added over 25 minutes with stirring to a solution of l-methylindazole-3-carbonyl chloride [10.1 g] in toluene [250 ml] at room temperature. The suspension was stirred for 1.5 hours, then allowed to stand overnight. The white solid was collected by filtration, washed with toluene, then hexane and dried in the oven at 75°C to give the title compound. Yield 22.1 g (92.3%)
MS analysis gave the expected molecular weight (432) for the free base of the title compound. After recrystallisation from isopropanol the product melted at 233 to 234°C and gave the following elemental analysis:
Found C 65.73, H 7.03, N i l.60;
C26H33N4CIO2. 0.33H2O requires C 65.74, H 7.14, N 11.80%
c) N-(endo-9-methyl-9-azabicyclo-[3 ,l]-non-3-yI)-l-methylindazole-3- carboxamide monohydrochloride [granisetron (1)].
N-4-Methoxybenzyl-N-(endo-9-methyl-9-azabicyclo-[3,3,l]-non-3-yl)-l- methylindazole-3-carboxamide monohydrochloride (1.00 g) and methane sulphonic acid (5.0 ml) were heated at 70°C with stirring for 20 minutes. TLC showed a strong spot corresponding to granisetron and confirmed that no starting material remained. The cooled mixture was poured into ice cold water, and the product isolated following the method of Example 1(d). Yield 0.57 g (76.6%) IR and NMR spectroscopy confirmed that the product was granisetron.
Example 3 N-(endo-9-Methyl-9-azabicycio-[3 ,l]-non-3-yl)-l-methylindazole-3- carboxamide monohydrochloride [granisetron (1)].
N-4-Methoxybenzyl-N-(endo-9-methyl-9-azabicyclo-[3,3,l]-non-3-yl)-l- methylindazole-3-carboxamide monohydrochloride (1.00 g) was stirred in • trifluoroacetic acid (4.0 ml) at room temperature. After an initial vigorous reaction, the mixture was warmed briefly to 70°C and examined by TLC, which confirmed that the reaction was complete. The mixture was poured into ice cold water (100 ml) and filtered. The filtrate was made alkaline and extracted with dichloromethane (100 ml). The product was isolated from this extract following the method of Example 1(d). Yield 0.41 g (55.0%). IR and NMR spectroscopy confirmed that the product was granisetron.
Example 4
9-Methyl-9-azabicyclo[3.3.1]nonan-3-one (Ref: Org. Synth Coll Vol. 4. 816) is heated under reflux in toluene with benzylamine with p-toluene sulphonic acid catalysis to give 3-benzimino-9-methyl-9-azabicyclo[3.3.1]nonane. This is reduced with sodium cyanoborohydride in tetrahydrofuran to give 3-benzylamino-9-methyl-9- azabicyclo[3.3.1]nonane. The latter is reacted with l-methylindazole-3-carboxylic acid chloride in dichloromethane to give N-benzyl-endo-N-(9-methyl-9- azabicyclo[3.3.1 ] non- 3-yl)- 1 -methylindazole- 3-carboxamide.

Claims

Claims:
1. A process for preparing granisetron (1) or a pharmaceutically acceptable salt thereof:
Figure imgf000009_0001
(1) granisetron
which process comprises deprotecting a compound of Structure (2).
Figure imgf000009_0002
(2)
wherein R is a nitrogen-protecting group which does not significantly reduce the nucleophilicity of a secondary amino group, and optionally forming a pharmaceutically acceptable salt.
2. A process according to Claim 1 in which R is benzyl, substituted benzyl, t- butyl, allyl, or a silyl group.
3. A process according to Claim 1 or Claim 2 in which R is benzyl, substituted with one or more chloro, methyl or methoxy groups.
4. A compound of Structure (2)
Figure imgf000010_0001
(2)
wherein R is a nitrogen-protecting group which does not significantly reduce the nucleophilicity of a secondary amino group.
5. A compound of Structure (4)
Figure imgf000010_0002
(4)
wherein R is a nitrogen-protecting group which does not significantly reduce the nucleophilicity of a secondary amino group, provided that R is not benzyl.
6. A compound of Claim 4 or Claim 5 in which R is benzyl, substituted benzyl, t-butyl, allyl, or a silyl group.
7. A compound of Claim 4 or Claim 5 in which R is benzyl, substituted with one or more chloro, methyl or methoxy groups.
8. A compound of Claim 7 which is: (a) N-benzyl-N-(endo-9-methyl-9-azabicyclo-[3,3,l]-non-3-yl)-l-methylindazole- 3-carboxamide,
(b) N-4-methoxybenzyl-N-(endo-9-methyl-9-azabicyclo-[3,3,l]-non-3-yl)-l- methylindazole-3-carboxamide, or
(c) endo-3-(4-methoxybenzylamino)-9-methyl-9-azabicyclo-[3,3,l]-nonane, or an acid addition salt thereof.
9. Granisetron whenever prepared by a process according to any one of Claims 1 to 3.
PCT/EP1995/000764 1994-03-03 1995-02-28 Process for the preparation of an indazole-3-carboxamide derivative WO1995023799A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69510186T DE69510186D1 (en) 1994-03-03 1995-02-28 METHOD FOR PRODUCING INDAZOL-3-CARBONAMIDE DERIVATES
EP95912187A EP0748321B1 (en) 1994-03-03 1995-02-28 Process for the preparation of an indazole-3-carboxamide derivative
MX9603818A MX9603818A (en) 1994-03-03 1995-02-28 Process for the preparation of an indazole-3-carboxamide derivative.
JP52270295A JP4034339B2 (en) 1994-03-03 1995-02-28 Method for producing indazole-3-carboxamide derivative
GR990402203T GR3031121T3 (en) 1994-03-03 1999-08-31 Process for the preparation of an indazole-3-carboxamide derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9404055.7 1994-03-03
GB9404055A GB9404055D0 (en) 1994-03-03 1994-03-03 Novel process

Publications (1)

Publication Number Publication Date
WO1995023799A1 true WO1995023799A1 (en) 1995-09-08

Family

ID=10751194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/000764 WO1995023799A1 (en) 1994-03-03 1995-02-28 Process for the preparation of an indazole-3-carboxamide derivative

Country Status (9)

Country Link
EP (1) EP0748321B1 (en)
JP (1) JP4034339B2 (en)
AT (1) ATE181073T1 (en)
DE (1) DE69510186D1 (en)
ES (1) ES2132650T3 (en)
GB (1) GB9404055D0 (en)
GR (1) GR3031121T3 (en)
MX (1) MX9603818A (en)
WO (1) WO1995023799A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124163A1 (en) * 1995-03-01 1999-01-16 Smithkline Beecham Plc New process for obtaining pharmaceutically active compounds
ES2125162A1 (en) * 1995-03-25 1999-02-16 Smithkline Beecham Plc Process for preparing a pharmaceutically active compound
ES2129349A1 (en) * 1996-02-13 1999-06-01 Smithkline Beecham Plc Process for the preparation of granisetron
AT406051B (en) * 1995-02-10 2000-02-25 Smithkline Beecham Plc NEW PROCEDURE
AT406770B (en) * 1995-03-01 2000-08-25 Smithkline Beecham Plc Novel process for the preparation of granisetron
WO2003080606A1 (en) * 2002-03-26 2003-10-02 Laboratorios Vita, S.A. Process for preparing a pharmaceutically active compound (granisetron)
WO2007088557A1 (en) * 2006-02-01 2007-08-09 Natco Pharma Limited Process for highly pure crystalline granisetron base
EP2323654A1 (en) * 2008-08-19 2011-05-25 ScinoPharm Taiwan, Ltd. Polymorphic form of granisetron hydrochloride and methods of making the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081054A2 (en) * 1978-12-30 1983-06-15 Beecham Group Plc Azabicyclo alkyl derivatives
EP0200444A2 (en) * 1985-04-27 1986-11-05 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-HT antagonist activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081054A2 (en) * 1978-12-30 1983-06-15 Beecham Group Plc Azabicyclo alkyl derivatives
EP0200444A2 (en) * 1985-04-27 1986-11-05 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-HT antagonist activity

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406051B (en) * 1995-02-10 2000-02-25 Smithkline Beecham Plc NEW PROCEDURE
ES2124163A1 (en) * 1995-03-01 1999-01-16 Smithkline Beecham Plc New process for obtaining pharmaceutically active compounds
AT406770B (en) * 1995-03-01 2000-08-25 Smithkline Beecham Plc Novel process for the preparation of granisetron
AT407637B (en) * 1995-03-01 2001-05-25 Smithkline Beecham Plc NEW METHOD FOR PRODUCING GRANISETRON
ES2125162A1 (en) * 1995-03-25 1999-02-16 Smithkline Beecham Plc Process for preparing a pharmaceutically active compound
AT406678B (en) * 1995-03-25 2000-07-25 Smithkline Beecham Plc METHOD FOR PRODUCING GRANISETRON OR A PHAMRAZEUTICALLY ACCEPTABLE SALT THEREOF
ES2129349A1 (en) * 1996-02-13 1999-06-01 Smithkline Beecham Plc Process for the preparation of granisetron
WO2003080606A1 (en) * 2002-03-26 2003-10-02 Laboratorios Vita, S.A. Process for preparing a pharmaceutically active compound (granisetron)
US7071209B2 (en) 2002-03-26 2006-07-04 Laboratorios Vita, S.A. Process for preparing a pharmaceutically active compound (granisetron)
WO2007088557A1 (en) * 2006-02-01 2007-08-09 Natco Pharma Limited Process for highly pure crystalline granisetron base
EP2323654A1 (en) * 2008-08-19 2011-05-25 ScinoPharm Taiwan, Ltd. Polymorphic form of granisetron hydrochloride and methods of making the same
EP2323654A4 (en) * 2008-08-19 2012-10-24 Scinopharm Taiwan Ltd Polymorphic form of granisetron hydrochloride and methods of making the same

Also Published As

Publication number Publication date
GR3031121T3 (en) 1999-12-31
ATE181073T1 (en) 1999-06-15
EP0748321B1 (en) 1999-06-09
MX9603818A (en) 1997-03-29
ES2132650T3 (en) 1999-08-16
GB9404055D0 (en) 1994-04-20
EP0748321A1 (en) 1996-12-18
JP4034339B2 (en) 2008-01-16
JPH09509673A (en) 1997-09-30
DE69510186D1 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
JP5091913B2 (en) Quinoline derivatives and their use as 5-HT6 ligands
EP1963323B1 (en) Novel diazabicyclic aryl derivatives and their medical use
PL168468B1 (en) Method of obtaining novel esters of thienylocarboxylic acid and amine alcohols as well as products of their fourth-order reactions
IL154187A (en) Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterial agents
EP0255297A2 (en) Azabicyclic compounds, process for their preparation, and their pharmaceutical use
JPH046684B2 (en)
US4882327A (en) Certain heterocyclic N-substituted carboxamides
CA2092431C (en) 3,9-diazabicyclo (3.3.1) nonan-7-yl derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
EP0748321B1 (en) Process for the preparation of an indazole-3-carboxamide derivative
CA2098729A1 (en) Azabicyclic amides or esters of halogenated benzoic acids
US4826839A (en) Azabicyclic benzamide derivatives
JPH0559050A (en) 3-quinuclidine derivative
WO1991001316A1 (en) New 9-azabicyclo[3.3.1]nonane-derivate
JPH08231544A (en) Chemical intermediate
JPH09501954A (en) Imidazo [5,1-c] [1,4] benzoxazin-1-one imidazolylalkyl derivatives and processes for their preparation
EP0525879A1 (en) Pyrazole derivatives
EP0882045B1 (en) Process for the preparation of granisetron
EP0927163B1 (en) Preparation of 1-butyl-4-piperidinylmethylamine
EP0055546B1 (en) Pentacyclic compounds, processes for their preparation and their use
JP3657986B2 (en) Imidazo [1,5-a] indol-3-one imidazolylalkyl derivatives and methods for their preparation
AU2005209382A1 (en) Method for producing a 2-(ethoxymethyl)tropane derivative
US7714129B2 (en) Methods of preparing anhydrous aripiprazole form II
US4187312A (en) 3-Hydroxy-4,4-dimethyl-5-pyrrolidone derivatives
JPS62246572A (en) Anti-bronchospasmodic n-alkyl-nortropine esters and quaternary derivatives of same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995912187

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 702646

Date of ref document: 19960828

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995912187

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995912187

Country of ref document: EP